lonamo duo 50mg/850mg potahovaná tableta
egis pharmaceuticals plc, budapešť array - 41 monohydrÁt sitagliptin-hydrochloridu; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a sitagliptin
sitagliptin mylan 100mg potahovaná tableta
viatris limited, dublin array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 100mg - sitagliptin
sitagliptin stada 100mg potahovaná tableta
stada arzneimittel ag, bad vilbel array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 100mg - sitagliptin
sitagliptin sandoz 100mg potahovaná tableta
sandoz s.r.o., praha array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 100mg - sitagliptin
sitagliptin polpharma 100mg potahovaná tableta
zaklady farmaceutyczne polpharma sa, starogard gdański array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 100mg - sitagliptin
sitagliptin polpharma 25mg potahovaná tableta
zaklady farmaceutyczne polpharma sa, starogard gdański array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 25mg - sitagliptin
sitagliptin polpharma 50mg potahovaná tableta
zaklady farmaceutyczne polpharma sa, starogard gdański array - 41 monohydrÁt sitagliptin-hydrochloridu - potahovaná tableta - 50mg - sitagliptin
maymetsi 50mg/1000mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17555 sitagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/1000mg - metformin a sitagliptin
maymetsi 50mg/850mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 17555 sitagliptin; 2418 metformin-hydrochlorid - potahovaná tableta - 50mg/850mg - metformin a sitagliptin
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.